Key result
Advanced imaging and biochemical testing facilitate early detection and targeted management of cardiac amyloidosis.
Answers are grounded in this paper and cite their sources.
This review outlines a systematic approach incorporating recent advances in cardiac imaging and biochemical diagnosis to facilitate early recognition and targeted management of cardiac amyloidosis, thereby improving patient prognosis.
Advances in cardiac imaging have resulted in greater recognition of cardiac amyloidosis in everyday clinical practice, but the diagnosis continues to be made in patients with late-stage disease, suggesting that more needs to be done to improve awareness of its clinical manifestations and the potential of therapeutic intervention to improve prognosis. Light chain cardiac amyloidosis, in particular, if recognized early and treated with targeted plasma cell therapy, can be managed very effectively. For patients with transthyretin amyloidosis, there are numerous therapies that are currently in late-phase clinical trials. In this review, we address common questions encountered in clinical practice regarding etiology, clinical presentation, diagnosis, and management of cardiac amyloidosis, focusing on recent important developments in cardiac imaging and biochemical diagnosis. The aim is to show how a systematic approach to the evaluation of suspected cardiac amyloidosis can impact the prognosis of patients in the modern era.
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2017) conducted a review in Cardiac amyloidosis (light chain and transthyretin amyloidosis). Systematic evaluation using recent advances in cardiac imaging and biochemical diagnosis facilitates early recognition and targeted management of light chain and transthyretin cardiac amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: